STOCK TITAN

Inovio Pharmaceuticals Inc - INO STOCK NEWS

Welcome to our dedicated news page for Inovio Pharmaceuticals (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inovio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inovio Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
Rhea-AI Summary
INOVIO receives orphan drug designation from the European Commission for INO-3107, a product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP). The designation acknowledges the high unmet medical need for this disease and provides regulatory and financial incentives for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
Rhea-AI Summary
INOVIO to report first quarter 2023 financial results on May 10, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Inovio Pharmaceuticals Inc

Nasdaq:INO

INO Rankings

INO Stock Data

257.78M
22.99M
1.61%
17.98%
9%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
San Diego

About INO

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.